Centessa Pharmaceuticals plc (CNTA)

Centessa Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	15	-	6.85	-	-
Revenue Growth	-	-	-	-	-	-
Gross Profit	-	15	-	6.85	-	-
Selling, General & Admin	58.02	50.47	50.81	53.73	55.2	43.01
Research & Development	198.67	172.22	150.24	124.41	155.08	96.32
Operating Expenses	256.69	222.69	201.06	178.14	210.28	139.33
Operating Income	-256.69	-207.69	-201.06	-171.28	-210.28	-139.33
Interest Expense	-11.31	-11.46	-10.09	-9.91	-7.28	-2.55
Interest & Investment Income	17.78	20.53	14.02	10.48	0.24	-
Currency Exchange Gain (Loss)	0.9	2.9	-1.8	0.8	-2.8	-3.6
Other Non Operating Income (Expenses)	-0.04	0.01	0.11	-0.33	-0.76	-0.77
EBT Excluding Unusual Items	-249.37	-195.71	-198.82	-170.24	-220.87	-146.25
Other Unusual Items	-	-	-34.1	-5.9	3.92	-15.08
Pretax Income	-249.37	-195.71	-232.91	-176.14	-216.95	-381.79
Income Tax Expense	1.27	1.82	2.84	-25.06	-0.75	0.11
Net Income	-250.64	-197.53	-235.76	-151.09	-216.21	-381.9
Preferred Dividends & Other Adjustments	-	-	-	-	-	-0.83
Net Income to Common	-250.64	-197.53	-235.76	-151.09	-216.21	-381.07
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	141	136	114	96	93	75
Shares Outstanding (Diluted)	141	136	114	96	93	75
Shares Change	14.73%	18.56%	19.02%	2.97%	24.26%	401.11%
EPS (Basic)	-1.78	-1.46	-2.06	-1.57	-2.31	-5.07
EPS (Diluted)	-1.78	-1.46	-2.06	-1.57	-2.31	-5.07
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	-209.17	-194.19	-142.09	-160.51	-201.68	-136.34
Free Cash Flow Per Share	-1.49	-1.43	-1.24	-1.67	-2.16	-1.81
Gross Margin	-	100.00%	-	100.00%	-	-
Operating Margin	-	-1384.61%	-	-2499.39%	-	-
Profit Margin	-	-1316.88%	-	-2204.66%	-	-
Free Cash Flow Margin	-	-1294.59%	-	-2342.20%	-	-
EBITDA	-256.35	-207.37	-200.71	-170.97	-210.15	-139.3
D&A For EBITDA	0.34	0.32	0.34	0.31	0.13	0.03
EBIT	-256.69	-207.69	-201.06	-171.28	-210.28	-139.33

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error